Savara Inc. Reports $37.3 Million Net Loss in Q1 2026, Increases Operating Expenses

Savara Inc. reported a net loss of $37.3 million for the first quarter of 2026, compared to a net loss of $26.6 million for the same period in 2025, reflecting an increase of approximately 40%. The company's total operating expenses rose to $39.0 million, up from $28.4 million year-over-year, driven primarily by a 22% increase in research and development expenses, which reached $23.4 million. General and administrative expenses also saw a significant rise, increasing by 68% to $15.6 million, largely due to higher personnel costs and stock-based compensation.

As of March 31, 2026, Savara's cash and cash equivalents stood at $38.8 million, with short-term investments totaling $164.0 million. This represents a decrease in total current assets from $241.6 million at the end of 2025 to $209.3 million. The company’s accumulated deficit increased to approximately $645.4 million, reflecting ongoing investments in its clinical programs without generating product revenue. The increase in operating expenses and net loss is attributed to the continued development of its investigational inhaled biologic, MOLBREEVI, for the treatment of autoimmune pulmonary alveolar proteinosis.

Strategically, Savara has made significant progress with its product candidate, MOLBREEVI, which is currently in Phase 3 development. The company submitted a Biologics License Application (BLA) to the FDA, which has been granted Priority Review, and the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for review. The FDA has extended the review period for the BLA to November 22, 2026, due to a major amendment in response to information requests. These developments indicate a focused effort on regulatory approval, which is critical for the company's future revenue generation.

Operationally, Savara has continued to expand its clinical trial activities and partnerships. The company has engaged contract research organizations and manufacturers to support its clinical development efforts. As of the end of the first quarter, Savara had approximately 253.3 million shares outstanding, reflecting an increase in share count due to stock options and restricted stock units. The company’s workforce remains primarily remote, with a significant portion of its employees dedicated to research and development activities.

Looking ahead, Savara anticipates continued operating losses as it invests in the development and commercialization of MOLBREEVI. The company acknowledges the need for additional capital to fund its ongoing operations and clinical trials, emphasizing that future funding will depend on the pace of clinical development and regulatory outcomes. Savara's management remains focused on achieving regulatory approvals and preparing for potential commercialization, while also managing its financial resources to sustain operations through the development phase.